In contrast to agonist monoclonal antibodies, both C-terminal truncated form and full length form of Pleiotrophin failed to activate vertebrate ALK (anaplastic lymphoma kinase)?
about
Anaplastic lymphoma kinase: signalling in development and diseaseMolecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugsStructural studies reveal an important role for the pleiotrophin C-terminus in mediating interactions with chondroitin sulfateFAM150A and FAM150B are activating ligands for anaplastic lymphoma kinaseInternalization and down-regulation of the ALK receptor in neuroblastoma cell lines upon monoclonal antibodies treatmentUnderstanding the Interplay between Expression, Mutation and Activity of ALK Receptor in Rhabdomyosarcoma Cells for Clinical Application of Small-Molecule InhibitorsEffect of single-chain antibody targeting of the ligand-binding domain in the anaplastic lymphoma kinase receptor.ALK-rearrangements and testing methods in non-small cell lung cancer: a reviewThe synthetic peptide P111-136 derived from the C-terminal domain of heparin affin regulatory peptide inhibits tumour growth of prostate cancer PC-3 cells.ALK-activating homologous mutations in LTK induce cellular transformation.The Drosophila midkine/pleiotrophin homologues Miple1 and Miple2 affect adult lifespan but are dispensable for alk signaling during embryonic gut formation.Pleiotrophin as a central nervous system neuromodulator, evidences from the hippocampus.Augmentor α and β (FAM150) are ligands of the receptor tyrosine kinases ALK and LTK: Hierarchy and specificity of ligand-receptor interactionsTargeting ALK in neuroblastoma--preclinical and clinical advancements.Heparin-binding protein pleiotrophin: an important player in the angiogenic process.Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy.ALK: a tyrosine kinase target for cancer therapy.Anaplastic lymphoma kinase as a therapeutic target.The heparin-binding growth factor midkine: the biological activities and candidate receptors.From top to bottom: midkine and pleiotrophin as emerging players in immune regulation.The constitutive activity of the ALK mutated at positions F1174 or R1275 impairs receptor trafficking.Anaplastic Lymphoma Kinase in Cutaneous MalignanciesA novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer's disease.The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC).Monoclonal Antibodies against the MET/HGF Receptor and Its Ligand: Multitask Tools with Applications from Basic Research to Therapy.Heparin is an activating ligand of the orphan receptor tyrosine kinase ALK.
P2860
Q24312329-16C8F3DE-6A6D-44F9-9545-65E944E1C00EQ26769659-B8483B65-B6E0-4B5D-BB7C-82B17A756F7DQ27704056-95F43B59-329B-47F7-96C6-30C5857EC617Q28118071-8E58F5E4-3B74-49DD-9E53-633C2934FC47Q28482066-1ADAE2C2-4735-4FB0-8A65-EDCC6D3B6617Q28546245-8A7D8E9C-0501-4A09-93AB-AC3F284B7EA4Q33487136-937DB26B-32FC-43D0-8DE7-B8BE0442C023Q33776835-CFF6038D-03C8-4748-B6A1-3BDC324611A2Q33915644-3FCB1351-70EB-459B-B258-F0115455FD7AQ34162940-A3C5DCE1-5A5A-434C-B6DC-B3CA6EA673B7Q34473183-23304C9F-CF3D-47EB-901A-282079C5C3F8Q34869224-94431978-589E-4541-A467-FFC56C0CB936Q36435120-096E5E2A-7FAA-4150-8524-ACEB567466CAQ36933081-A72A9556-A7C7-47ED-A2D5-9F3C186168F9Q37228534-1DD40FD7-7024-4881-9408-2308D69A24DFQ37411178-1256DAFE-49F6-4483-9EBA-EE242A0D3BE7Q37518624-18B32986-A2A9-4CEE-B6C1-C52943EE4CF6Q38045455-BADE4650-5CCE-40DC-AEB8-94935EB2481EQ38102670-B9986E4E-1B87-4934-8F86-48C0E65139CDQ39207404-B6F57865-5B4E-4A2D-BD05-E659B995811CQ39606679-498D77B6-5EEB-40DE-9A64-5E79B023E221Q41670874-5F21B2E2-9B40-467F-891E-B29EA46E2040Q42684122-FADEF7B0-A833-43CA-A27A-B160587F4F59Q49887874-D94AA2BB-33A6-457D-A130-00C949EA3253Q53789447-B19C681D-AEA5-4BDC-805A-D4505A04D3DBQ54295628-DFB635D0-C9D9-4501-9291-F67EFA23E89E
P2860
In contrast to agonist monoclonal antibodies, both C-terminal truncated form and full length form of Pleiotrophin failed to activate vertebrate ALK (anaplastic lymphoma kinase)?
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
In contrast to agonist monoclo ...... (anaplastic lymphoma kinase)?
@en
type
label
In contrast to agonist monoclo ...... (anaplastic lymphoma kinase)?
@en
prefLabel
In contrast to agonist monoclo ...... (anaplastic lymphoma kinase)?
@en
P1433
P1476
In contrast to agonist monoclo ...... (anaplastic lymphoma kinase)?
@en
P2093
Marc Vigny
Pierre Mazot
P304
P356
10.1016/J.CELLSIG.2007.07.011
P577
2007-07-25T00:00:00Z